Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-7691
Authors: | Pradhan, Swetalina Schwartz, Robert Patil, Anant Grabbe, Stephan Goldust, Mohamad |
Title: | Treatment options for leishmaniasis |
Online publication date: | 7-Sep-2022 |
Year of first publication: | 2022 |
Language: | english |
Abstract: | Leishmaniasis is broadly classified into three types: cutaneous, mucocutaneous and visceral. The visceral form is most dangerous and can result in death. Although leishmaniasis is an ancient disease, its treatment is still challenging. Several drugs, differing in their cost, toxicity, treatment duration and emergence of drug resistance, are used for different types of leishmaniasis. To overcome these limitations, the search for newer drugs and other treatments continues. In this article, we discuss conventional drugs, other treatments, including newer options such as immunotherapy and immunochemotherapy, and future prospects for leishmaniasis treatment. |
DDC: | 610 Medizin 610 Medical sciences |
Institution: | Johannes Gutenberg-Universität Mainz |
Department: | FB 04 Medizin |
Place: | Mainz |
ROR: | https://ror.org/023b0x485 |
DOI: | http://doi.org/10.25358/openscience-7691 |
Version: | Published version |
Publication type: | Zeitschriftenaufsatz |
License: | CC BY |
Information on rights of use: | https://creativecommons.org/licenses/by/4.0/ |
Journal: | Clinical and experimental dermatology 47 3 |
Pages or article number: | 516 521 |
Publisher: | Wiley-Blackwell |
Publisher place: | Oxford u.a |
Issue date: | 2022 |
ISSN: | 1365-2230 |
Publisher DOI: | 10.1111/ced.14919 |
Appears in collections: | JGU-Publikationen |
Files in This Item:
File | Description | Size | Format | ||
---|---|---|---|---|---|
treatment_options_for_leishma-20220907103110563.pdf | 77.84 kB | Adobe PDF | View/Open |